CRISM Therapeutics Corporation
AMMCF
$6.77
$6.573,309.57%
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | -211.00K | -211.00K | -4.61M | -4.61M | -531.00K |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -109.50K | -109.50K | 3.55M | 3.55M | -588.50K |
| Change in Net Operating Assets | -- | -- | -- | -- | -- |
| Cash from Operations | -320.50K | -320.50K | -1.06M | -1.06M | -1.12M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -17.50M | -17.50M | 17.50M | 17.50M | -- |
| Other Investing Activities | 17.97M | 17.97M | -500.00K | -500.00K | -581.50K |
| Cash from Investing | 465.50K | 465.50K | 17.00M | 17.00M | -254.50K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | 0.00 |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -1.08M | -1.08M | -14.65M | -14.65M | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -1.08M | -1.08M | -14.65M | -14.65M | 623.00K |
| Foreign Exchange rate Adjustments | 36.00K | 36.00K | 34.50K | 34.50K | -- |
| Miscellaneous Cash Flow Adjustments | -334.00K | -334.00K | -- | -- | -- |
| Net Change in Cash | -1.23M | -1.23M | 1.32M | 1.32M | -770.00K |
